MEDGENERA
  • Sections
    • NEWLY PUBLISHED
    • News from Asia-pacific
    • News from Europe
    • News from USA
    • MEDGENERA ORIGINAL
    • ASSESSMENT
    • MARKET INSIGHTS
    • DRUG TRIAL
    • PROGRESSIVE REVIEW
    • APPS & IMPLANTS
  • About us
  • Plans
  • Education
  • Get Online Training
  • Login
  • Webinar
0
  • Login
  • Get 1-Free month
  • Online Course
  • About us
  • BIORISE
  • Plans
  • BUSINESS
  • CAREER
  • HEALTHCARE & MEDICINE
  • IN-DEPTH STORIES
  • KNOWLEDGE CENTRE
  • MEDGENERA EXCLUSIVE
  • NEWLY PUBLISHED
  • News from Asia-pacific
  • News from Europe
  • News from USA
  • RESOURCE CENTRES
  • TECHNOLOGY

Category: BRIEFING

Proportion
Tiash SahaMay 22, 2018

First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved

2016 founded company, Dova Pharma's first drug, Doptelet received US FDA approval as the first oral treatment option to reduce the risk of blood loss in patients with chronic liver disease.

Proportion
Tiash SahaMay 8, 2018

Melinta Therapeutics Receives CARB-X Funding to Develop New Antibiotics Against Multiple “Superbugs”

No new class of antibiotics has been approved over the last fifty years. Currently, there are 10 new classes of antibiotics in the CARB-X portfolio, if any one of them reaches to patients, it would be the first new class of antibiotic to be approved, since 1962. Melinta Therapeutics funding.

Proportion
Tiash SahaMay 2, 2018

First CAR-T GeneTherapy for Pediatric Blood Cancer ‘Kymriah’ Now Treats Adult Patients

Novartis' Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.

Proportion
Tiash SahaApril 26, 2018

First Drug to Treat Polycystic Kidney Disease Bags FDA Approval

First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.

Proportion
Vikash KumarApril 23, 2018

This Cancer Biotech Startup Raises Over 40% Higher in IPO than Proposed Goal

The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.

Proportion
Tiash SahaApril 18, 2018

AstraZeneca Commits $90 Million in 5 Years to Improve Healthcare in India

Over the next five years, pharma giant, AstraZeneca will invest $90 million in India to improve the overall health outcomes in the country, by promoting innovation, skill development, and quality manufacturing.

Proportion
Tiash SahaApril 13, 2018

First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production

Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.

Proportion
Vikash KumarApril 12, 2018

Delhi-Based Healthcare Fintech Startup Raises $1 M in Seed Funding Round

Delhi-based healthcare financing startup, LetsMD has raised $1 million a pre-series A funding round led by SRI Capital.

Proportion
Tiash SahaApril 12, 2018

First AI-Based Diabetic Retinopathy Detection Device Gets FDA Approval

The artificial intelligence (AI) based device called IDx-DR received US FDA approval for the screening of diabetic retinopathy- a common eye disease in diabetic patients that could lead to vision impairment and blindness.

Proportion
Tiash SahaApril 4, 2018

Potential New Medicine ‘Moxetumomab Pasudotox’ under FDA Priority Review for a Rare Leukemia

AstraZeneca’s leukemia drug, Moxetumomab pasudotox has received Priority Review designation from the US FDA for the treatment of adult patients ...

  • 1
  • 2
  • 3
Privacy Policy Terms Payment Policy Education Contact Us About us